Abstract
The Role of PCSK9 Inhibitors in Preventing Coronary Artery Disease
Highlights
Publication History: Lipid-lowering therapy with statins has been established as effective treatment for preventing cardiovascular events
Several clinical studies have demonstrated that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein (LDL) cholesterol significantly when added to statin therapy [1,2]
Several clinical studies have demonstrated that PCSK9 inhibitors significantly reduce LDL cholesterol levels when added to statin therapy
Summary
Ryo Naito and Takatoshi Kasai2,3* 1Department of Cardiovascular Medicine, Juntendo University Urayasu Hospital, Japan 2Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Japan 3Department of Cardiovascular Medicine, Juntendo University School of Medicine, Japan
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
